Mechanism

Pharmacology

What the molecule does, from the moment you swallow it. Most of what makes a trip frightening has a plain mechanical explanation.

Psilocybin is a prodrug

Psilocybin itself is largely inactive. It is 4-phosphoryloxy-N,N-dimethyltryptamine, and the phosphate group is stripped off by alkaline phosphatase, in the gut and elsewhere in the body, to produce psilocin, which is the molecule that actually does something. The conversion is fast and thorough: intact psilocybin is essentially undetectable in blood after an oral dose.

Absorption and conversion are why oral onset takes twenty to sixty minutes rather than being immediate. People commonly report that lemon tek and tea come on faster. That is plausible, since the material is already broken up and partly extracted, but the idea that acid converts psilocybin to psilocin before you swallow it has not been demonstrated, and no study has measured how much either method changes the timeline.

Psilocin is structurally close to serotonin. The difference is two methyl groups on the terminal nitrogen and the position of the hydroxyl. That similarity is the entire story. It is close enough to fit serotonin receptors, and different enough to behave differently once it is in one.

What it binds

5-HT2A: The receptor that matters. Psilocin is a partial agonist here, and this is where the psychedelic effect comes from. The evidence is direct: pre-treating volunteers with ketanserin, a 5-HT2A antagonist, blocked psilocybin’s effects in a dose-dependent way.
5-HT2C: Also bound. Its contribution to the experience is less clear than 5-HT2A’s.
5-HT1A: Bound with reasonable affinity. Appears to modulate anxiety, and may be part of why the experience is so sensitive to circumstances.
Dopamine receptors: Not meaningfully. This is worth stating because it is the pharmacological reason psilocybin has essentially no addiction liability. There is no direct reinforcement pathway of the kind stimulants and opioids act on.

What that does to the brain

5-HT2A receptors are dense on layer V pyramidal neurons in the cortex, cells that coordinate communication between brain regions. Agonism there increases their excitability, and the system-level result is a loosening of the usual segregation between networks that normally stay relatively separate.

A widely cited imaging finding involves the default mode network, the set of regions associated with self-referential thought. In an early fMRI study, psilocybin reduced activity in its hub regions and weakened the coupling between the medial prefrontal and posterior cingulate cortex, and the size of the medial prefrontal decrease predicted how intense people found the experience.

Two cautions. Imaging correlations are not explanations, and the popular framing of psychedelics as “resetting” the brain runs considerably ahead of the evidence. What is established is that connectivity patterns change acutely. What that means for lasting change is still being worked out.

Metabolism and clearance

Psilocin is cleared mainly by glucuronidation (psilocin-O-glucuronide is the main metabolite found in urine) and by conversion to 4-hydroxyindole-3-acetic acid (4-HIAA). Laboratory work implicates monoamine oxidase A in that second route, with CYP2D6 and CYP3A4 also able to metabolise psilocin, though how much each contributes in people is not settled. In controlled studies plasma psilocin peaked on average about two hours after an oral dose (individual studies range from under two to about four hours), with an elimination half-life of roughly one and a half to three hours.

Two consequences follow. First, subjective effects track plasma psilocin closely, which is why the timeline is predictable enough for a countdown to be broadly honest here in a way it would not be for most drugs. Second, blocking one of the clearance routes is expected to change how much psilocin is around and for how long, which is one reason MAO inhibitors are treated as unpredictable: the size of the effect has not been measured in people.

The timeline, and why it is that shape

Waiting

0–30 min

Nothing has started yet. Your body is still absorbing psilocybin and converting it to psilocin. That takes 20 to 60 minutes.

Coming up

30–90 min

Psilocin is entering your bloodstream and binding 5-HT2A receptors. Effects will keep building for about an hour.

Peak

90–180 min

Psilocin in your blood is at its highest. Normal communication between brain networks is loosened. This is the strongest it gets.

Coming down

180–300 min

Psilocin is clearing. Its half-life is roughly two hours, so the level in your blood is now falling steadily.

Afterglow

300–420 min

The main effects are over. What is left is tiredness, some residual mood change and a nervous system that has had a long day.

Toxicity

Psilocybin has one of the widest margins between an active dose and a lethal one of any psychoactive drug that has been compared. A 2004 comparison of twenty substances estimated its lethal dose at roughly a thousand times the commonly used dose, among the widest margins in that comparison, and far more mushroom than anyone could realistically eat. Deaths directly attributed to psilocybin are extremely rare, and the reported cases involve serious pre-existing heart disease or other drugs; a misidentified mushroom is a far more realistic way for mushroom-picking to kill someone.

The real risks are elsewhere, and they’re worth knowing:

Behavioural

Falls, traffic, water, heights. Almost every physical injury associated with psilocybin comes from impaired judgement in an ordinary environment, not from the drug's action on the body.

Cardiovascular

Psilocybin raises heart rate and blood pressure modestly. Irrelevant for most people; not irrelevant for someone with significant cardiac disease or an arrhythmia.

Psychiatric

Can precipitate or worsen psychosis in people with schizophrenia, or with a first-degree family history of it, and can trigger mania in bipolar disorder. This is the exclusion criterion every clinical trial uses.

Drug interactions

The lithium seizure signal is real and substantial. MAOIs make the experience unpredictable, and irreversible MAOIs carry their own blood-pressure risks. These are documented concerns, unlike the frequently overstated SSRI serotonin syndrome risk.

HPPD

Hallucinogen persisting perception disorder, lasting visual disturbance after the drug has cleared. Genuinely rare, poorly understood, and more often reported after repeated heavy use.

Lasting distress

A minority of people report a difficult experience that stays difficult for a long time. In a survey of nearly 2,000 people describing their worst mushroom experience, 7.6% of those whose experience was more than a year earlier had sought treatment for lasting psychological symptoms. Difficulty rose with dose, and risky behaviour was more likely without physical comfort and social support.